Anaplastic Lymphoma Kinase (ALK) has become a crucial target in oncology, particularly for cancers such as non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL). Since its discovery, ALK has driven precision medicine approaches, enabling the development of targeted therapies that improve patient outcomes. The ALK Market continues to evolve, offering opportunities for...